MA55364A - Bioconjugués d'antigènes polysaccharidiques o d'e. coli, procédés de production de ces derniers, et méthodes d'utilisation de ces derniers - Google Patents

Bioconjugués d'antigènes polysaccharidiques o d'e. coli, procédés de production de ces derniers, et méthodes d'utilisation de ces derniers

Info

Publication number
MA55364A
MA55364A MA055364A MA55364A MA55364A MA 55364 A MA55364 A MA 55364A MA 055364 A MA055364 A MA 055364A MA 55364 A MA55364 A MA 55364A MA 55364 A MA55364 A MA 55364A
Authority
MA
Morocco
Prior art keywords
methods
bioconjugates
coli
producing
polysaccharidic
Prior art date
Application number
MA055364A
Other languages
English (en)
Inventor
Darren Robert Abbanat
Martin Edward Braun
Pieter Jan Burghout
Sandmeier Maria Paula Carranza
Kellen Cristhina Fae
Fonck Veronica Gambillara
Jeroen Geurtsen
Yon Patricia Ibarra
Stefan Jochen Kemmler
Michael Thomas Kowarik
Manuela Mally
Jan Theunis Poolman
Eveline Marleen Weerdenburg
Original Assignee
Glaxosmithkline Biologicals Sa
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa, Janssen Pharmaceuticals Inc filed Critical Glaxosmithkline Biologicals Sa
Publication of MA55364A publication Critical patent/MA55364A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MA055364A 2019-03-18 2020-03-18 Bioconjugués d'antigènes polysaccharidiques o d'e. coli, procédés de production de ces derniers, et méthodes d'utilisation de ces derniers MA55364A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962819746P 2019-03-18 2019-03-18

Publications (1)

Publication Number Publication Date
MA55364A true MA55364A (fr) 2022-01-26

Family

ID=70285927

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055364A MA55364A (fr) 2019-03-18 2020-03-18 Bioconjugués d'antigènes polysaccharidiques o d'e. coli, procédés de production de ces derniers, et méthodes d'utilisation de ces derniers

Country Status (25)

Country Link
US (3) US11446370B2 (fr)
EP (1) EP3941516A1 (fr)
JP (1) JP7370391B2 (fr)
KR (1) KR102532707B1 (fr)
CN (1) CN113924112A (fr)
AR (1) AR118388A1 (fr)
AU (1) AU2020240072A1 (fr)
BR (1) BR112021018236A2 (fr)
CA (1) CA3134216A1 (fr)
CL (1) CL2021002426A1 (fr)
CO (1) CO2021013823A2 (fr)
CR (1) CR20210522A (fr)
EA (1) EA202192390A1 (fr)
IL (1) IL286394B2 (fr)
JO (1) JOP20210256A1 (fr)
MA (1) MA55364A (fr)
MX (1) MX2021011445A (fr)
MY (1) MY205586A (fr)
PE (1) PE20212265A1 (fr)
PH (1) PH12021552155A1 (fr)
SA (1) SA521430310B1 (fr)
SG (1) SG11202110301TA (fr)
TW (1) TWI751513B (fr)
UY (1) UY38616A (fr)
WO (1) WO2020191082A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038915T2 (hu) 2013-01-17 2018-12-28 Arsanis Biosciences Gmbh MDR E. colira fajlagos antitest
NZ723328A (en) 2014-02-24 2018-01-26 Glycovaxyn Ag Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
CR20210522A (es) 2019-03-18 2021-12-17 Janssen Pharmaceuticals Inc Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
US20230226175A1 (en) 2020-06-25 2023-07-20 Glaxosmithkline Biologicals Sa Modified exotoxin a proteins
PE20231385A1 (es) 2020-09-17 2023-09-12 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y usos de las mismas
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
IL301880A (en) 2020-11-30 2023-06-01 Janssen Pharmaceuticals Inc Analytical method for glycoconjugation using a capillary-based immunoassay system
MX2023011697A (es) 2021-04-01 2023-10-19 Janssen Pharmaceuticals Inc Produccion de bioconjugados o18 de e. coli.
KR20240005684A (ko) 2021-04-08 2024-01-12 얀센 파마슈티칼즈, 인코포레이티드 바이오컨쥬게이트 생산 방법
CN116003531B (zh) * 2022-12-28 2023-09-05 山东省农业科学院畜牧兽医研究所 噬菌体受体结合蛋白po86在大肠杆菌o抗原血清型分型鉴定中的应用
EP4478050A1 (fr) 2023-06-12 2024-12-18 Janssen Pharmaceuticals, Inc. Procédé de quantification d'acétate lié dans des glycoconjugués

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700612A (en) 1971-06-23 1972-10-24 Tenneco Chem Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422653D0 (en) 1984-09-07 1984-10-10 Technology Licence Co Ltd Monoclonal antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
AUPM399594A0 (en) 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
AU743114B2 (en) 1997-04-01 2002-01-17 Corixa Corporation Aqueous immunologic adjuvant compositions of monophosphoryl lipid A
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
WO2001078777A2 (fr) 2000-04-13 2001-10-25 Mossman, Sally COMPOSITIONS IMMUNOSTIMULANTES COMPRENANT UN PHOSPHATE D'AMINOALKYL GLUCOSAMINIDE ET DU QS-21
AU2001253568A1 (en) 2000-04-18 2001-10-30 Dan C. Deborde Lipopolysaccharide-conjugate vaccine for sepsis treatment
RU2189253C1 (ru) 2001-04-09 2002-09-20 Государственный научный центр прикладной микробиологии Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
DK1481057T3 (da) 2002-03-07 2006-05-15 Eidgenoess Tech Hochschule System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
AU2005229434B2 (en) 2004-03-30 2010-09-30 Nsgene A/S Therapeutic use of a growth factor, NsG33
ES2535084T3 (es) 2005-05-11 2015-05-05 Eth Zurich Proteínas N-glicosiladas recombinantes procedentes de células procariotas
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CA2646891A1 (fr) 2006-03-23 2007-09-27 Novartis Ag Composes de potentialisation immunitaire
JP4791866B2 (ja) 2006-03-24 2011-10-12 国立大学法人秋田大学 下痢原性大腸菌感染症の判別に用いられる固相等
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009036379A2 (fr) 2007-09-14 2009-03-19 Adimab, Inc. Bibliothèques d'anticorps synthétiques rationnelles et leurs utilisations
CN102037004A (zh) 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
SI2257307T1 (sl) 2008-02-20 2018-09-28 Glaxosmithkline Biologicals S.A. Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic
MX2011011376A (es) 2009-04-27 2012-04-20 Immuron Ltd Preparacion de inmunoglobulina enriquecida con anti-lps, para utilizarse en tratamiento y/o profilaxis de un trastorno patologico.
CA2764374C (fr) 2009-06-05 2019-11-19 Infectious Disease Research Institute Adjuvants lipidiques synthetiques a base de glucopyranosyle
NO2501406T3 (fr) 2009-11-19 2018-05-19
MX381912B (es) 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
US20130273098A1 (en) 2010-12-10 2013-10-17 Jeffrey T. Blue Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
CA2847621A1 (fr) 2011-09-06 2013-03-14 Glycovaxyn Ag Vaccins bioconjugues fabriques dans des cellules procaryotes
US9932598B2 (en) 2012-08-02 2018-04-03 The Regents Of The University Of California Metabolic engineering of microbial organisms
WO2014037585A1 (fr) 2012-09-10 2014-03-13 Glycovaxyn Ag Bioconjugués comprenant des antigènes modifiés et leurs utilisations
KR20150068998A (ko) 2012-10-12 2015-06-22 글리코박신 아게 숙주 세포 변형 방법
CA2896157A1 (fr) 2012-12-27 2014-07-03 Glycovaxyn Ag Procedes et compositions se rapportant a crm197
HUE038915T2 (hu) 2013-01-17 2018-12-28 Arsanis Biosciences Gmbh MDR E. colira fajlagos antitest
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
BR112016007727A8 (pt) 2013-10-11 2018-01-30 Glycovaxyn Ag célula hospedeira, e, método para produzir uma proteína n-glicosilada.
CN106163550A (zh) 2013-12-04 2016-11-23 格林考瓦因有限公司 通过大肠杆菌中合成的糖蛋白疫苗预防金黄色葡萄球菌感染
KR102301188B1 (ko) 2014-02-06 2021-09-13 엑스4 파마슈티컬스 (오스트리아) 게엠베하 이. 콜라이 특이성 항체 서열
NZ723328A (en) 2014-02-24 2018-01-26 Glycovaxyn Ag Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
MX378857B (es) 2014-04-17 2025-03-10 Glaxosmithkline Biologicals Sa Celulas huespedes modificadas y usos de las mismas.
CN105695497B (zh) 2014-11-27 2019-09-24 中国人民解放军军事医学科学院生物工程研究所 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用
SI3240895T1 (sl) 2014-12-30 2022-04-29 Glaxosmithkline Biologicals S.A. Sestavki in postopki za glikozilacijo proteinov
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711635D0 (en) * 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
CR20210522A (es) 2019-03-18 2021-12-17 Janssen Pharmaceuticals Inc Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
FR3098334B1 (fr) 2019-07-05 2021-07-23 Airbus Operations Sas Procédé et système de surveillance d’un état de conscience d’un opérateur dans un poste de pilotage d’un aéronef
PE20231385A1 (es) 2020-09-17 2023-09-12 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y usos de las mismas

Also Published As

Publication number Publication date
AR118388A1 (es) 2021-09-29
TWI751513B (zh) 2022-01-01
US11446370B2 (en) 2022-09-20
MY205586A (en) 2024-10-28
AU2020240072A1 (en) 2021-10-28
IL286394B2 (en) 2025-10-01
EP3941516A1 (fr) 2022-01-26
PH12021552155A1 (en) 2022-08-15
US11931405B2 (en) 2024-03-19
SA521430310B1 (ar) 2023-12-13
WO2020191082A1 (fr) 2020-09-24
JP7370391B2 (ja) 2023-10-27
IL286394B1 (en) 2025-06-01
IL286394A (en) 2021-10-31
WO2020191082A9 (fr) 2020-11-05
CN113924112A (zh) 2022-01-11
BR112021018236A2 (pt) 2021-11-23
KR20210141586A (ko) 2021-11-23
JP2022533883A (ja) 2022-07-27
CR20210522A (es) 2021-12-17
JOP20210256A1 (ar) 2023-01-30
UY38616A (es) 2020-09-30
US20240316172A1 (en) 2024-09-26
MX2021011445A (es) 2021-10-13
SG11202110301TA (en) 2021-10-28
CL2021002426A1 (es) 2022-04-29
CO2021013823A2 (es) 2022-03-29
KR102532707B1 (ko) 2023-05-12
CA3134216A1 (fr) 2020-09-24
PE20212265A1 (es) 2021-11-30
TW202102255A (zh) 2021-01-16
US20230118878A1 (en) 2023-04-20
EA202192390A1 (ru) 2021-12-03
US20200316184A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
CA189124S (fr) Boucle d'oreille
CA189957S (fr) Boucle d'oreille
CA189234S (fr) Boucle d'oreille
MX2025006133A (es) Conjugado de anticuerpo-derivado de pirrolobenzodiazepina
CA200053S (fr) Boucle d'oreille
IL286394A (en) Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
MX2025001900A (es) Construcciones de anticuerpos anti-ror
EP4295840A3 (fr) Polymères glycane et procédés associés
MA55365A (fr) Procédés de production de bioconjugués de polysaccharides o-antigènes d' e. coli, compositions de ceux-ci et leurs procédés d'utilisation
MX393879B (es) Métodos de preparación de niraparib.
MX2019011758A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
EP3655001A4 (fr) Méthodes d'aphérèse et utilisations associées
PL3840756T3 (pl) Ulepszona synteza 1,4-diazaspiro[5.5]undekan-3-onu
EP3578712A4 (fr) Agent de traitement destiné à traiter des fibres, fibres et procédé de production associé, et feuille de fibres et procédé de production associé
DK3762341T3 (da) Glassammensætninger, glassammensætninger til fremstilling af glasfibre, og glasfibre fremstillet deraf
LT3979827T (lt) Maistinė kompozicija, apimanti 2‘-fukozillaktozę ir 3‘-galaktozillaktozę
EP3853352A4 (fr) Plaque de puits fonctionnalisée, procédés de préparation et d'utilisation de celle-ci
EA201990915A1 (ru) Новые модуляторы 5-гидрокситриптаминового рецептора 7 и способ их применения
EP3573618A4 (fr) Compositions et méthodes de production d'hémoglobine
SA519410213B1 (ar) تركيبات بولي أميد متفرعة منتهية
EP3838926C0 (fr) Amidon modifié, utilisation associée, et procédé de production d'amidon modifié
EP3813811A4 (fr) Compositions et méthodes de médiation d'eps
CY1125463T1 (el) Διαμορφωτες διαυλου καλιου
MA51323A (fr) Matière souple, procédé d'obtention et ses utilisations
CA3156248A1 (fr) Conjugues anticorps anti-cd37-maytansine et methodes d'utilisation de ceux-ci